Nimodipine in the management of preeclampsia

Maternal and fetal effects

Michael A. Belfort, George Saade, Kenneth J. Moise, Arcadia Cruz, Karolina Adam, Wayne Kramer, Brian Kirshon

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

OBJECTIVE: Our purpose was to determine the effects of orally administered nimodipine on selected maternal and fetal parameters in patients with preeclampsia. STUDY DESIGN: Ten consecutive patients were given 30 mg of nimodipine orally every 4 hours from admission until 24 hours after delivery. Maternal and fetal cerebral blood velocity, umbilical artery blood velocity, fetal heart rate variability, maternal blood pressure and heart rate, and transplacental passage of the drug were studied. All 10 patients were delivered within 24 hours of the first dose of nimodipine. RESULTS: There was an acute and significant reduction in the pulsatility index in the smaller diameter maternal cerebral arteries (ophthalmic and central retinal) and in the fetal middle cerebral artery. The umbilical artery systolic/diastolic ratio was also significantly reduced. Maternal blood pressure was controlled without the need for other antihypertensive medication, and although there was an increase in heart rate after administration of the drug, it was well tolerated. Nimodipine reached significant maternal and fetal levels within 2 hours. CONCLUSIONS: Nimodipine is rapidly absorbed after oral administration and has significant maternal and fetal cerebral vasodilator activity. It is an effective, easily administered antihypertensive agent when used in patients with preeclampsia.

Original languageEnglish (US)
Pages (from-to)417-424
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume171
Issue number2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Nimodipine
Pre-Eclampsia
Mothers
Umbilical Arteries
Antihypertensive Agents
Heart Rate
Blood Pressure
Fetal Heart Rate
Cerebral Arteries
Middle Cerebral Artery
Maternal Inheritance
Vasodilator Agents
Fetal Blood
Pharmaceutical Preparations
Oral Administration

Keywords

  • antihypertensive
  • cerebral blood flow
  • Nimodipine
  • preeclampsia

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Nimodipine in the management of preeclampsia : Maternal and fetal effects. / Belfort, Michael A.; Saade, George; Moise, Kenneth J.; Cruz, Arcadia; Adam, Karolina; Kramer, Wayne; Kirshon, Brian.

In: American Journal of Obstetrics and Gynecology, Vol. 171, No. 2, 1994, p. 417-424.

Research output: Contribution to journalArticle

Belfort, Michael A. ; Saade, George ; Moise, Kenneth J. ; Cruz, Arcadia ; Adam, Karolina ; Kramer, Wayne ; Kirshon, Brian. / Nimodipine in the management of preeclampsia : Maternal and fetal effects. In: American Journal of Obstetrics and Gynecology. 1994 ; Vol. 171, No. 2. pp. 417-424.
@article{78bee516b9a8422490ba29f09d3ebdda,
title = "Nimodipine in the management of preeclampsia: Maternal and fetal effects",
abstract = "OBJECTIVE: Our purpose was to determine the effects of orally administered nimodipine on selected maternal and fetal parameters in patients with preeclampsia. STUDY DESIGN: Ten consecutive patients were given 30 mg of nimodipine orally every 4 hours from admission until 24 hours after delivery. Maternal and fetal cerebral blood velocity, umbilical artery blood velocity, fetal heart rate variability, maternal blood pressure and heart rate, and transplacental passage of the drug were studied. All 10 patients were delivered within 24 hours of the first dose of nimodipine. RESULTS: There was an acute and significant reduction in the pulsatility index in the smaller diameter maternal cerebral arteries (ophthalmic and central retinal) and in the fetal middle cerebral artery. The umbilical artery systolic/diastolic ratio was also significantly reduced. Maternal blood pressure was controlled without the need for other antihypertensive medication, and although there was an increase in heart rate after administration of the drug, it was well tolerated. Nimodipine reached significant maternal and fetal levels within 2 hours. CONCLUSIONS: Nimodipine is rapidly absorbed after oral administration and has significant maternal and fetal cerebral vasodilator activity. It is an effective, easily administered antihypertensive agent when used in patients with preeclampsia.",
keywords = "antihypertensive, cerebral blood flow, Nimodipine, preeclampsia",
author = "Belfort, {Michael A.} and George Saade and Moise, {Kenneth J.} and Arcadia Cruz and Karolina Adam and Wayne Kramer and Brian Kirshon",
year = "1994",
doi = "10.1016/0002-9378(94)90277-1",
language = "English (US)",
volume = "171",
pages = "417--424",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Nimodipine in the management of preeclampsia

T2 - Maternal and fetal effects

AU - Belfort, Michael A.

AU - Saade, George

AU - Moise, Kenneth J.

AU - Cruz, Arcadia

AU - Adam, Karolina

AU - Kramer, Wayne

AU - Kirshon, Brian

PY - 1994

Y1 - 1994

N2 - OBJECTIVE: Our purpose was to determine the effects of orally administered nimodipine on selected maternal and fetal parameters in patients with preeclampsia. STUDY DESIGN: Ten consecutive patients were given 30 mg of nimodipine orally every 4 hours from admission until 24 hours after delivery. Maternal and fetal cerebral blood velocity, umbilical artery blood velocity, fetal heart rate variability, maternal blood pressure and heart rate, and transplacental passage of the drug were studied. All 10 patients were delivered within 24 hours of the first dose of nimodipine. RESULTS: There was an acute and significant reduction in the pulsatility index in the smaller diameter maternal cerebral arteries (ophthalmic and central retinal) and in the fetal middle cerebral artery. The umbilical artery systolic/diastolic ratio was also significantly reduced. Maternal blood pressure was controlled without the need for other antihypertensive medication, and although there was an increase in heart rate after administration of the drug, it was well tolerated. Nimodipine reached significant maternal and fetal levels within 2 hours. CONCLUSIONS: Nimodipine is rapidly absorbed after oral administration and has significant maternal and fetal cerebral vasodilator activity. It is an effective, easily administered antihypertensive agent when used in patients with preeclampsia.

AB - OBJECTIVE: Our purpose was to determine the effects of orally administered nimodipine on selected maternal and fetal parameters in patients with preeclampsia. STUDY DESIGN: Ten consecutive patients were given 30 mg of nimodipine orally every 4 hours from admission until 24 hours after delivery. Maternal and fetal cerebral blood velocity, umbilical artery blood velocity, fetal heart rate variability, maternal blood pressure and heart rate, and transplacental passage of the drug were studied. All 10 patients were delivered within 24 hours of the first dose of nimodipine. RESULTS: There was an acute and significant reduction in the pulsatility index in the smaller diameter maternal cerebral arteries (ophthalmic and central retinal) and in the fetal middle cerebral artery. The umbilical artery systolic/diastolic ratio was also significantly reduced. Maternal blood pressure was controlled without the need for other antihypertensive medication, and although there was an increase in heart rate after administration of the drug, it was well tolerated. Nimodipine reached significant maternal and fetal levels within 2 hours. CONCLUSIONS: Nimodipine is rapidly absorbed after oral administration and has significant maternal and fetal cerebral vasodilator activity. It is an effective, easily administered antihypertensive agent when used in patients with preeclampsia.

KW - antihypertensive

KW - cerebral blood flow

KW - Nimodipine

KW - preeclampsia

UR - http://www.scopus.com/inward/record.url?scp=0028111834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028111834&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(94)90277-1

DO - 10.1016/0002-9378(94)90277-1

M3 - Article

VL - 171

SP - 417

EP - 424

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -